Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002002 · ClinicalTrials.gov registry record · NA
A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome
A NA study, sponsored by Lederle Laboratories.
- Completed
- Registry status
- NA
- Development phase
NCT00002002: Completed NA study, sponsored by Lederle Laboratories.
NCT00002002 is a NA study that has completed, run by Lederle Laboratories. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002002, a NA study, has completed, sponsored by Lederle Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The primary objective of the study is to evaluate the effectiveness of l-leucovorin in preventing toxicity from high dose trimethoprim / sulfamethoxazole (TMP / SMX) used as a therapy for Pneumocystis carinii pneumonia (PCP) in patients with AIDS.
Interventions
- DRUG Leucovorin calcium
- DRUG Trimethoprim
- DRUG Sulfamethoxazole
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002002
The ClinicalTrials.gov registry entry for NCT00002002 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Lederle Laboratories, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leucovorin calcium is the first listed.
NCT00002002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002002 about?
NCT00002002 is a clinical study titled "A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome". The primary objective of the study is to evaluate the effectiveness of l-leucovorin in preventing toxicity from high dose trimethoprim / sulfamethoxazole (TMP / SMX) used as a therapy for Pneumocystis carinii pneumonia (PCP) in patients with AIDS.
What is the current status of trial NCT00002002?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002002?
The interventions under investigation include: Leucovorin calcium (DRUG), Trimethoprim (DRUG), Sulfamethoxazole (DRUG).
Who is sponsoring clinical trial NCT00002002?
This trial is sponsored by Lederle Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.